Irisin levels in type 2 diabetes mellitus with and without non-alcoholic fatty liver disease: a case-control study
DOI:
https://doi.org/10.56782/pps.254Keywords:
Irisin, Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Insulin SensitivityAbstract
Background: Fatty liver disease, particularly non-alcoholic fatty liver disease (NAFLD), affects around 25% of adults globally and up to 40% in developed countries. Often coexisting with type 2 diabetes mellitus (T2DM), NAFLD is linked to insulin resistance and metabolic syndrome. Irisin, a myokine induced by exercise, shows promise in enhancing insulin sensitivity, reducing hepatic steatosis, and improving metabolic health. Despite its potential, further research is needed to fully understand irisin's mechanisms and clinical implications in NAFLD and T2DM.
Objectives: This study investigates the irisin levels in T2DM patients with and without NAFLD and compares them with healthy controls.
Methods: A case-control study has been conducted involving 90 T2DM patients and 90 healthy controls, aged 30-55 years, recruited from SCB Medical College, Cuttack, between September 2021 and August 2022. Participants were screened for NAFLD using the Hepatosis Steatosis Index (HSI) and divided into four groups: T2DM with NAFLD, T2DM without NAFLD, controls with NAFLD, and controls without NAFLD. Serum irisin levels were measured using ELISA. Anthropometric data, physical activity, and various biochemical parameters were assessed and analyzed.
Results: The irisin levels were significantly lower in T2DM patients compared to healthy controls
(p = 0.001). Among T2DM patients, those with NAFLD had lower irisin levels than those without NAFLD, though not statistically significant (p = 0.299). Significant correlations were observed between irisin levels and insulin sensitivity markers such as HOMA-IR and QUICKI across different groups.
Conclusion: Lower irisin levels in T2DM patients, particularly those with NAFLD, highlight its potential role in the pathogenesis of metabolic disorders. Further research is needed to elucidate irisin's therapeutic implications in T2DM and NAFLD.
Downloads
References
Dharmalingam, M.; Yamasandhi, P.G. Nonalcoholic fatty liver disease and Type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2018, 22, Art. No: 421. DOI: 10.4103/ijem.IJEM_585_17 DOI: https://doi.org/10.4103/ijem.IJEM_585_17
Boström, P.; Wu, J.; Jedrychowski, M.P.; Korde, A.; Ye, L.; Lo, J.C.; et al. A PGC1α-dependent myokine that drives browning of white fat and thermogenesis. Nature 2011, 481, 463–468. DOI: 10.1038/nature10777 DOI: https://doi.org/10.1038/nature10777
Zhang, T.; Yi, Q.; Huang, W.; Feng, J.; Liu, H. New insights into the roles of Irisin in diabetic cardiomyopathy and vascular diseases. Biomed. Pharmacother. 2024, 175, Art. No: 116631. DOI: 10.1016/j.biopha.2024.116631 DOI: https://doi.org/10.1016/j.biopha.2024.116631
Hu, J.; Ke, Y.; Wu, F.; Liu, S.; Ji, C.; Zhu, X.; et al. Circulating Irisin Levels in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterol. Res. Pract. 2020, 2020, Art. No: 8818191. DOI: 10.1155/2020/8818191 DOI: https://doi.org/10.1155/2020/8818191
Hou, N.; Liu, Y.; Han, F.; et al. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice. J. Mol. Cell. Cardiol. 2016, 99, 188–196. DOI: 10.1016/j.yjmcc.2016.09.005 DOI: https://doi.org/10.1016/j.yjmcc.2016.09.005
Zhang, Y.; Li, R.; Meng, Y.; et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 2014, 63, 514–525. DOI: 10.2337/db13-1106 DOI: https://doi.org/10.2337/db13-1106
Wang, C.; Wang, L.; Li, W.; et al. Irisin has no effect on lipolysis in 3T3-L1 adipocytes or fatty acid metabolism in HepG2 hepatocytes. Endocrine 2015, 49, 90–96. DOI: 10.1007/s12020-014-0458-9 DOI: https://doi.org/10.1007/s12020-014-0458-9
Zhang, H.J.; Zhang, X.F.; Ma, Z.M.; Pan, L.L.; Chen, Z.; et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J. Hepatol. 2013, 59, 557–562. DOI: 10.1016/j.jhep.2013.04.030 DOI: https://doi.org/10.1016/j.jhep.2013.04.030
Polyzos, S.A.; Kountouras, J.; Anastasilakis, A.D.; Geladari, E.V.; Mantzoros, C.S. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014, 63, 207–217. DOI: 10.1016/j.metabol.2013.09.013
World Health Organization. Diagnosis and management of type 2 diabetes (HEARTS-D). Geneva: World Health Organization; 2020. WHO/UCN/NCD/20.1. Available online: https://www.who.int/publications/i/item/9789240062147 (accessed on 9 August 2019).
World Health Organization. Global Physical Activity Questionnaire (GPAQ) Analysis Guide. Geneva: World Health Organization; 2016. Available online: https:// www.who.int/publications/m/item/global-physical-activity-questionnaire (accessed on 9 August 2019).
Kosmalski, M.; Drzewoski, J.; Szymczak-Pajor, I.; Zieleniak, A.; Mikołajczyk-Solińska, M.; Kasznicki, J.; Śliwińska, A. Irisin is related to non-alcoholic fatty liver disease (NAFLD). Biomedicines 2022, 10, Art. No: 2253. DOI: 10.3390/biomedicines10092253 DOI: https://doi.org/10.3390/biomedicines10092253
Bazick, J.; Donithan, M.; Neuschwander Tetri, B.A.; Kleiner, D.; Brunt, E.M.; Wilson, L.; et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: Guidelines for referral in NAFLD. Diabetes Care 2015, 38, 1347–1355. DOI: https://doi.org/10.2337/dc14-1239
Lee, J.H.; Kim, D.; Kim, H.J.; et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 2010, 42, 503–508. DOI: 10.1016/j.dld.2009.08.002 DOI: https://doi.org/10.1016/j.dld.2009.08.002
Jiang, Z.G.; de Boer, I.H.; Mackey, R.H.; et al. Associations of insulin resistance, inflammation and liver synthetic function with very low-density finlipoprotein: The Cardiovascular Health Study. Metabolism 2016, 65, 92–99. DOI: 10.1016/j.metabol.2015.10.017 DOI: https://doi.org/10.1016/j.metabol.2015.10.017
Shanaki, M.; Moradi, N.; Emamgholipour, S.; Fadaei, R.; Poustchi, H. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab. Syndr. 2017, 11, S467–S472. DOI: https://doi.org/10.1016/j.dsx.2017.03.037
Choi, E.S.; Kim, M.K.; Song, M.K.; et al. Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees. PLoS One 2014, 9, Art. No: e110680. DOI: https://doi.org/10.1371/journal.pone.0110680
Mahmoodnia, L.; Sadoughi, M.; Ahmadi, A.; Kafeshani, M. Relationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients. J. Renal Inj. Prev. 2017, 6, 88–92. DOI: 10.15171/jrip.2017.17 DOI: https://doi.org/10.15171/jrip.2017.17
Wen, M.S.; Wang, C.Y.; Lin, S.L.; Hung, K.C. Decrease in irisin in patients with chronic kidney disease. PLoS One 2013, 8, Art. No: e64025. DOI: https://doi.org/10.1371/journal.pone.0064025
Liu, J.J.; Liu, S.; Wong, M.D.; Tan, C.S.; Tavintharan, S.; Sum, C.F.; et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J. Diabetes Complicat. 2014, 28, 208–213. DOI: 10.1016/j.jdiacomp.2013.09.011 DOI: https://doi.org/10.1016/j.jdiacomp.2013.09.011
Polyzos, S.A.; Kountouras, J.; Anastasilakis, A.D.; Geladari, E.V.; Mantzoros, C.S. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014, 63, 207–217. DOI: https://doi.org/10.1016/j.metabol.2013.09.013
Ma, Y.; Wu, X.; Liu, X.; et al. Expression of irisin in liver tissue of patients with nonalcoholic fatty liver disease. J. Zhengzhou Univ. 2016, 51, 517–520.
Park, K.H.; Zaichenko, L.; Brinkoetter, M.; et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J. Clin. Endocrinol. Metab. 2013, 98, 4899–4907. DOI: https://doi.org/10.1210/jc.2013-2373
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Saffalya Nayak, Pratima Kumari Sahu, Roma Rattan, Srikrushna Mahapatra, Debjyoti Mohapatra
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
